Table 2 Baseline characteristics of HIV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008
Total N=1175 | HCV chronically infected patients N=1048 | Sustained HCV responders N=127 | |
|---|---|---|---|
CDC clinical stage: C, N (%) | 324 (27.8) | 300 (28.9) | 24 (19.2) |
Years since HIV diagnosis, median (IQR) | 18 (13-20) | 18 (13-20) | 18 (14-21) |
HIV transmission category, N (%) | |||
Intravenous drug use | 724 (62.0) | 651 (62.5) | 73 (57.9) |
Sexual | 318 (27.2) | 282 (27.1) | 36 (28.6) |
Transfusion | 85 (7.3) | 73 (7.0) | 12 (9.5) |
Other or unknown | 40 (3.4) | 35 (3.4) | 5 (4.0) |
Nadir CD4 (/μl), median (IQR) | 150 (66-248) | 146 (65-247) | 169 (96-251) |
CD4 cells count at initiation of antiretroviral treatment (/μl), median (IQR) | 242 (139-357) | 240 (132-354) | 256 (191-396) |
CD4 cells count at baseline (/μl), median (IQR) | 442 (304-633) | 438 (300-630) | 492 (345-662) |
CD4 cells count at baseline (/μl), N (%) | |||
<200 | 130 (11.2) | 126 (12.2) | 4 (3.1) |
200-350 | 251 (21.6) | 223 (21.6) | 28 (22.0) |
351-500 | 301 (25.9) | 269 (26.1) | 32 (25.2) |
>500 | 479 (41.3) | 416 (40.2) | 63 (49.6) |
Patients with <40 HIV RNA copies/ml, N (%) | 797 (68.8) | 702 (68.1) | 95 (74.8) |
Patients receiving HAART, N (%) | 841 (71.6) | 750 (71.6) | 91 (71.6) |
2 NRTI + 1 PI | 613 (52.2) | 552 (52.7) | 61 (48.0) |
2 NRTI + 1 NNRTI | 183 (15.6) | 158 (15.1) | 25 (19.7) |
1 NRTI + 1 NNRTI + 1 PI | 45 (3.8) | 40 (3.8) | 5 (3.9) |
Regimen including raltegravir | 26 (2.2) | 23 (2.2) | 3 (2.4) |